Business Context and Reporting Period
Company: Quantum-Si Inc (QSI)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2026
Business Overview: Quantum-Si is a life sciences company focused on proteomics research, offering single-molecule protein sequencing instruments (Platinum line) and consumables. The company is developing its next-generation platform, Proteus, currently estimated for commercial launch in Q2 2027.
Key Financial Metrics
| Metric (in thousands) | 3 Months Ended Jun 30, 2026 |
6 Months Ended Jun 30, 2026 |
6 Months Ended Jun 30, 2025 |
|---|---|---|---|
| Total Revenue | $344 | $602 | $1,433 |
| Gross Profit | $172 | $246 | $837 |
| Gross Margin | 50.0% | 40.9% | 58.4% |
| Net Loss | $(23,534) | $(45,205) | $(48,025) |
| Loss Per Share (Basic/Diluted) | $(0.11) | $(0.21) | $(0.26) |
| Operating Cash Flow | N/A | $(44,082) | $(46,351) |
| Cash & Marketable Securities | $169.9 million (as of Jun 30, 2026) | ||
| Total Debt | None reported (Operating lease liabilities only) |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 41.8% quarter-over-quarter and 58.0% year-over-year (six months). Management attributes this to customers deferring purchases of current Platinum instruments in anticipation of the Proteus platform launch.
- Margin Compression: Gross margin declined from 58.4% to 40.9% (six months) due to product mix shifts.
- Expense Reduction: Selling, general, and administrative (SG&A) expenses decreased 17.5% year-over-year (six months), primarily due to lower legal fees following the resolution of the Delaware Stockholder Litigation.
- Legal Settlement Resolution: The $3.4 million legal settlement expense recorded in the prior year was fully resolved in Q1 2026, with the remaining liability funded by insurance proceeds. No legal settlement expense was recorded in the current period.
- Warrant Liabilities: All Public and Private Warrants expired on June 10, 2026, resulting in a $0.8 million gain for the six-month period and eliminating the warrant liability from the balance sheet.
Guidance, Outlook, and Risks
- Proteus Launch Delay: The commercial launch of the Proteus platform has been delayed from late 2026 to the second quarter of 2027. Management expects this delay to continue to adversely impact revenue as customers wait for the new technology.
- Liquidity: As of June 30, 2026, the company held $169.9 million in cash and marketable securities. Management believes this is sufficient to fund operations for at least the next 12 months.
- Restructuring Program: On August 10, 2026, the company announced a restructuring program terminating approximately 20% of its workforce (approx. 30 employees). Expected one-time cash charges for severance are approximately $2.6 million, to be recognized in the second half of 2026.
- Nasdaq Compliance: On July 23, 2026, the company received a notice from Nasdaq regarding failure to maintain the $1.00 minimum bid price requirement. The company has until January 19, 2027, to regain compliance or risk delisting.
- Capital Needs: The company expects to continue incurring negative operating cash flows until it scales commercial operations. Future financing may be required via equity or debt offerings.
Investor Verification Checklist
- Proteus Timeline: Verify the feasibility of the new Q2 2027 launch date and the specific technical milestones required to meet it.
- Revenue Run Rate: Assess the extent of customer deferral and whether current revenue levels are sustainable until Proteus launches.
- Restructuring Costs: Confirm the $2.6 million severance estimate and the impact on future operating expenses.
- Nasdaq Status: Monitor the stock price to ensure it meets the $1.00 bid price requirement by the January 2027 compliance date to avoid delisting.
- Cash Burn Rate: Evaluate the $44.1 million operating cash burn over six months against the $169.9 million cash balance to determine the runway without additional financing.